Prevention of Peritoneal Metastases from Colon Cancer in High-Risk Patients: Preliminary Results of Surgery plus Prophylactic HIPEC

Paolo Sammartino, Simone Sibio, Daniele Biacchi, Maurizio Cardi, Fabio Accarpio, Pietro Mingazzini, Maria Sofia Rosati, Tommaso Cornali, Angelo Di Giorgio, Paolo Sammartino, Simone Sibio, Daniele Biacchi, Maurizio Cardi, Fabio Accarpio, Pietro Mingazzini, Maria Sofia Rosati, Tommaso Cornali, Angelo Di Giorgio

Abstract

The study compared the outcome in patients with advanced colonic cancer at high risk of peritoneal metastases (mucinous or signet-ring cell) without peritoneal or systemic spread, treated with standard colectomy or a more aggressive combined surgical approach. The study included patients with colonic cancer with clinical T3/T4, any N, M0, and mucinous or signet ring cell histology. The 25 patients in the experimental group underwent hemicolectomy, omentectomy, bilateral adnexectomy, hepatic round ligament resection, and appendectomy, followed by HIPEC. The control group comprised 50 patients treated with standard surgical resection during the same period in the same hospital by different surgical teams. Outcome data, morbidity, peritoneal recurrence rate, and overall, and disease-free survival, were compared. Peritoneal recurrence developed in 4% of patients in the experimental group and 22% of controls without increasing morbidity (P < 0.05). Actuarial overall survival curves disclosed no significant differences, whereas actuarial disease-free survival curves showed a significant difference between groups (36.8 versus 21.9 months, P < 0.01). A more aggressive preventive surgical approach combined with HIPEC reduces the incidence of peritoneal recurrence in patients with advanced mucinous colonic cancer and also significantly increases disease-free survival compared with a homogeneous control group treated with a standard surgical approach without increasing morbidity.

Figures

Figure 1
Figure 1
Overall survival.
Figure 2
Figure 2
Disease free survival.

References

    1. Chu DZJ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989;63(2):364–367.
    1. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358–363.
    1. Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. British Journal of Surgery. 2002;89(12):1545–1550.
    1. Gómez Portilla A, Cendoya I, López De Tejada I, et al. Peritoneal carcinomatosis of colorectal origin. Current treatment. Review and update. Revista Espanola de Enfermedades Digestivas. 2005;97(10):716–737.
    1. Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JWW, De Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. International Journal of Cancer. 2011;128(11):2717–2725.
    1. Nozoe T, Anai H, Nasu S, et al. Clinicopathological characteristics of mucinous carcinoma of the colon and rectum. Journal of Surgical Oncology. 2000;75(2):103–107.
    1. Kanemitsu Y, Kato T, Hirai T, et al. Survival after curative resection for mucinous adenocarcinoma of the colorectum. Diseases of the Colon and Rectum. 2003;46(2):160–167.
    1. Pande R, Sunga A, LeVea C, et al. Significance of signet-ring cells in patients with colorectal cancer. Diseases of the Colon and Rectum. 2008;51(1):50–55.
    1. Catalano V, Loupakis F, Graziano F, et al. Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. British Journal of Cancer. 2009;100(6):881–887.
    1. Song W, Wu SJ, He YL, et al. Clinicopathologic features and survival of patients with colorectal mucinous, signet-ring cell or non-mucinous adenocarcinoma: experience at an institution in southern China. Chinese Medical Journal. 2009;122(13):1486–1491.
    1. Koppe MJ, Boerman OC, Oyen WJG, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Annals of Surgery. 2006;243(2):212–222.
    1. Sugarbaker PH. Peritonectomy procedures. Annals of Surgery. 1995;221(1):29–42.
    1. Sugarbaker PH. Peritoneal Carcinomatosis: Principles of Management. Boston, Mass, USA: Kluwer Academic; 1996.
    1. Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Annals of Surgical Oncology. 2007;14(1):128–133.
    1. Verwaal VJ, Van Ruth S, De Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. Journal of Clinical Oncology. 2003;21(20):3737–3743.
    1. Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. Journal of Clinical Oncology. 2009;27(5):681–685.
    1. Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116(16):3756–3762.
    1. Verwaal VJ, Van Ruth S, Witkamp A, Boot H, Van Slooten G, Zoetmulder FAN. Long-term survival of peritoneal carcinomatosis of colorectal origin. Annals of Surgical Oncology. 2005;12(1):65–71.
    1. Elias D, Raynard B, Farkhondeh F, et al. Peritoneal carcinomatosis of colorectal origin: long-term results of intraperitoneal chemohyperthermia with oxaliplatin following complete cytoreductive surgery. Gastroenterologie Clinique et Biologique. 2006;30(10):1200–1204.
    1. Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric french study. Journal of Clinical Oncology. 2010;28(1):63–68.
    1. Cao C, Yan TD, Black D, Morris DL. A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Annals of Surgical Oncology. 2009;16(8):2152–2165.
    1. Dromain C, Leboulleux S, Auperin A, et al. Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT. Abdominal Imaging. 2008;33(1):87–93.
    1. Koh JL, Yan TD, Glenn D, Morris DL. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Annals of Surgical Oncology. 2009;16(2):327–333.
    1. Elit L, Oliver TK, Covens A, et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer. 2007;109(4):692–702.
    1. Scheithauer W, Kornek GV, Marczell A, et al. Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluououracil + levamisole for adjuvant therapy of resected colon carcinoma. British Journal of Cancer. 1998;77(8):1349–1354.
    1. Vaillant JC, Nordlinger B, Deuffic S, et al. Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: a multicenter phase III trial. Annals of Surgery. 2000;231(4):449–456.
    1. Nordlinger B, Rougier P, Arnaud JP, et al. Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial. Lancet Oncology. 2005;6(7):459–468.
    1. Elias D, Goéré D, Di Pietrantonio D, et al. Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. Annals of Surgery. 2008;247(3):445–450.
    1. Sugarbaker PH. Comprehensive management of disseminated colorectal cancer. Annals of Surgical Oncology. 2008;15(12):3327–3330.
    1. Maggiori L, Elias D. Curative treatment of colorectal peritoneal carcinomatosis: current status and future trends. European Journal of Surgical Oncology. 2010;36(7):599–603.
    1. Ripley RT, Davis JL, Kemp CD, Steinberg SM, Toomey MA, Avital I. Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases. Trials. 2010;11, article no. 62
    1. Nelson H, Petrelli N, Carlin A, et al. Guidelines 2000 for colon and rectal cancer surgery. Journal of the National Cancer Institute. 2001;93(8):583–596.
    1. Ogino S, Brahmandam M, Cantor M, et al. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Modern Pathology. 2006;19(1):59–68.
    1. World Health Organization. WHO Handbook for Reporting Results of Cancer Traetment. Geneva, Switzerland: WHO; 1979.
    1. Lefevre JH, Elias DM. Cytoreductive surgery plus intraperitoneal chemohyperthermia in patients with colorectal cancer at high risk for local-regional recurrence. Cancer Journal. 2009;15(3):200–203.
    1. Saxena A, Yan TD, Morris DL. A critical evaluation of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. World Journal of Surgery. 2010;34(1):70–78.
    1. Iafrate F, Ciolina M, Sammartino P, et al. Peritoneal carcinomatosis: imaging with 64-MDCT and 3T MRI with diffusion-weighted imaging. Abdominal Imaging. In press.
    1. Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer and Metastasis Reviews. 2003;22(4):465–472.
    1. Sugarbaker PH. Mucinous colorectal carcinoma. Journal of Surgical Oncology. 2001;77(4):282–283.
    1. Sugarbaker PH. It’s what the surgeon doesn’t see that kills the patient. Journal of Nippon Medical School. 2000;67(1):5–8.
    1. Gerber SA, Rybalko VY, Bigelow CE, et al. Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. American Journal of Pathology. 2006;169(5):1739–1752.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren